User:Mr. Ibrahem/Rosuvastatin
 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /roʊˈsuːvəstætɪn/ roh-SOO-və-stat-in |
| Trade names | Crestor, Rosulip, Zuvamor, others |
| Other names | Rosuvastatin calcium (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603033 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth (tablets) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 20%[2][3] |
| Protein binding | 88%[2][3] |
| Metabolism | Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized[2][3] |
| Metabolites | N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity)[4] |
| Elimination half-life | 19 hours[2][3] |
| Excretion | Feces (90%)[2][3] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H28FN3O6S |
| Molar mass | 481.539 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Rosuvastatin, sold under the trade name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.[3] It is recommended to be used together with dietary changes, exercise, and weight loss.[3] It is taken by mouth.[3]
Common side effects include abdominal pain, nausea, headaches, and muscle pains.[3] Serious side effects may include rhabdomyolysis, liver problems, and diabetes.[3] Use during pregnancy may harm the baby.[3] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.[3]
Rosuvastatin was patented in 1991, and approved for medical use in the United States in 2003.[3][6] It is available as a generic medication.[3] In the United States, the wholesale cost per dose is less than US$0.15 as of 2018[update].[7] In the United Kingdom, it costs the NHS one to two pounds for one month's treatment as of 2020.[8] In 2017, it was the 39th most commonly prescribed medication in the United States, with more than 19 million prescriptions.[9][10]
References[edit]
- ^ a b "Rosuvastatin Use During Pregnancy". Drugs.com. 27 September 2019. Archived from the original on 30 November 2020. Retrieved 14 March 2020.
- ^ a b c d e Aggarwal, RK; Showkathali, R (June 2013). "Rosuvastatin calcium in acute coronary syndromes". Expert Opinion on Pharmacotherapy. 14 (9): 1215–1227. doi:10.1517/14656566.2013.789860. PMID 23574635. Archived from the original on 29 August 2021. Retrieved 29 November 2019.
- ^ a b c d e f g h i j k l m n "Rosuvastatin Calcium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists (AHFS). Archived from the original on 24 December 2018. Retrieved 24 December 2018.
- ^ "Crestor- rosuvastatin calcium tablet, film coated". DailyMed. 9 November 2018. Archived from the original on 25 September 2020. Retrieved 14 March 2020.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 20 September 2020. Retrieved 9 September 2020.
- ^ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495. Archived from the original on 24 December 2018. Retrieved 24 December 2018.
- ^ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (CMS). Archived from the original on 19 December 2018. Retrieved 22 December 2018.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 217. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 14 March 2020.
- ^ "Rosuvastatin - Drug Usage Statistics". ClinCalc. 23 December 2019. Archived from the original on 11 April 2020. Retrieved 11 April 2020.